Eyenovia (NASDAQ:EYEN – Get Free Report) will likely be announcing its Q4 2024 earnings results before the market opens on Wednesday, May 21st. Analysts expect Eyenovia to post earnings of ($7.20) per share and revenue of $1.60 million for the quarter.
Eyenovia Stock Down 1.8%
NASDAQ EYEN opened at $1.15 on Wednesday. The stock’s 50 day moving average is $1.20 and its two-hundred day moving average is $7.35. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $3.25 million, a price-to-earnings ratio of -0.02 and a beta of 0.76. Eyenovia has a 1-year low of $0.85 and a 1-year high of $124.80.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “neutral” rating and issued a $2.00 target price on shares of Eyenovia in a research note on Friday, March 21st.
Eyenovia Company Profile
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
See Also
- Five stocks we like better than Eyenovia
- What Are Some of the Best Large-Cap Stocks to Buy?
- NVIDIA Stock Surges on Bullish News: How High Could It Climb?
- Consumer Staples Stocks, Explained
- Why Boeing May Be Ready to Take Off After Latest Developments
- ETF Screener: Uses and Step-by-Step Guide
- eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner?
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.